14-Aug-2026
Ten large-cap healthcare stocks with strong Quant scores amid sector-wide rally
Seeking Alpha News (Tue, 11-Aug 11:06 AM ET)
Corcept Therapeutics Ups 2026 Revenue Guidance as Lifyorli Launch Accelerates Growth
Market Chameleon (Thu, 30-Jul 7:13 AM ET)
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Business Wire (Wed, 29-Jul 4:05 PM ET)
Business Wire (Wed, 22-Jul 4:05 PM ET)
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
PRNewswire (Thu, 25-Jun 6:41 PM ET)
Business Wire (Wed, 17-Jun 4:28 PM ET)
Business Wire (Sat, 6-Jun 4:45 PM ET)
Business Wire (Fri, 29-May 4:33 PM ET)
Market Chameleon (Wed, 27-May 4:37 AM ET)
Business Wire (Wed, 27-May 8:00 AM ET)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Corcept Therapeutics trades on the NASDAQ stock market under the symbol CORT.
As of August 14, 2026, CORT stock price climbed to $114.47 with 695,316 million shares trading.
CORT has a beta of 1.37, meaning it tends to be more sensitive to market movements. CORT has a correlation of 0.03 to the broad based SPY ETF.
CORT has a market cap of $12.37 billion. This is considered a Large Cap stock.
Last quarter Corcept Therapeutics reported $256 million in Revenue and $.36 earnings per share. This beat revenue expectation by $37 million and exceeded earnings estimates by $.34.
In the last 3 years, CORT traded as high as $122.21 and as low as $20.84.
The top ETF exchange traded funds that CORT belongs to (by Net Assets): IJR, VTI, VB, FBT, VBK.
CORT has outperformed the market in the last year with a return of +59.0%, while the SPY ETF gained +21.5%. In the last 3 month period, CORT beat the market returning +96.3%, while SPY returned +4.0%. However, in the most recent 2 weeks CORT has underperformed the stock market by returning 0.0%, while SPY returned +3.9%.
CORT support price is $106.36 and resistance is $114.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CORT shares will trade within this expected range on the day.